BidaskClub downgraded shares of Ra Pharmaceuticals (NASDAQ:RARX) from a buy rating to a hold rating in a report issued on Friday morning, BidAskClub reports.

Other equities research analysts have also recently issued research reports about the stock. ValuEngine raised shares of Ra Pharmaceuticals from a buy rating to a strong-buy rating in a research report on Tuesday, July 2nd. Svb Leerink assumed coverage on shares of Ra Pharmaceuticals in a research report on Wednesday, May 22nd. They set an outperform rating and a $33.00 target price for the company. Raymond James cut shares of Ra Pharmaceuticals from a strong-buy rating to a market perform rating in a research report on Monday, July 29th. Robert W. Baird assumed coverage on shares of Ra Pharmaceuticals in a research report on Thursday, June 20th. They set an outperform rating for the company. Finally, BMO Capital Markets set a $42.00 target price on shares of Ra Pharmaceuticals and gave the company a buy rating in a research report on Wednesday, August 7th. Three investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of Buy and an average price target of $38.63.

Shares of RARX opened at $24.71 on Friday. The company has a 50 day moving average price of $28.98 and a 200-day moving average price of $26.01. Ra Pharmaceuticals has a fifty-two week low of $11.27 and a fifty-two week high of $36.96. The stock has a market capitalization of $1.16 billion, a PE ratio of -12.00 and a beta of 1.37. The company has a debt-to-equity ratio of 0.02, a quick ratio of 15.30 and a current ratio of 15.30.

Ra Pharmaceuticals (NASDAQ:RARX) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.03). Equities research analysts forecast that Ra Pharmaceuticals will post -1.97 EPS for the current year.

In other Ra Pharmaceuticals news, insider Simon Read sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $25.41, for a total transaction of $254,100.00. Following the transaction, the insider now owns 16,234 shares in the company, valued at approximately $412,505.94. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Ramin Farzaneh-Far sold 10,595 shares of the company’s stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $33.10, for a total transaction of $350,694.50. Following the transaction, the insider now owns 8,521 shares in the company, valued at approximately $282,045.10. The disclosure for this sale can be found here. Insiders have sold 54,047 shares of company stock valued at $1,547,392 in the last three months. 4.30% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently modified their holdings of the business. BlackRock Inc. increased its stake in Ra Pharmaceuticals by 27.9% during the 2nd quarter. BlackRock Inc. now owns 4,059,169 shares of the company’s stock valued at $122,061,000 after purchasing an additional 886,583 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Ra Pharmaceuticals by 19.4% in the second quarter. Vanguard Group Inc. now owns 1,564,112 shares of the company’s stock worth $47,033,000 after acquiring an additional 253,966 shares during the period. Candriam Luxembourg S.C.A. increased its stake in shares of Ra Pharmaceuticals by 15.0% in the second quarter. Candriam Luxembourg S.C.A. now owns 1,178,000 shares of the company’s stock worth $35,267,000 after acquiring an additional 154,000 shares during the period. VHCP Management II LLC increased its stake in shares of Ra Pharmaceuticals by 7.1% in the second quarter. VHCP Management II LLC now owns 677,164 shares of the company’s stock worth $20,362,000 after acquiring an additional 44,684 shares during the period. Finally, VHCP Management III LLC increased its stake in shares of Ra Pharmaceuticals by 12.7% in the second quarter. VHCP Management III LLC now owns 670,350 shares of the company’s stock worth $20,157,000 after acquiring an additional 75,637 shares during the period. Institutional investors and hedge funds own 91.59% of the company’s stock.

About Ra Pharmaceuticals

Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.

Featured Story: How to invest in blue-chip stocks

Analyst Recommendations for Ra Pharmaceuticals (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.